SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001815776-24-000015
Filing Date
2024-03-25
Accepted
2024-03-25 20:20:50
Documents
3
Period of Report
2024-03-21

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1711412440.html 3  
1 FORM 3 wk-form3_1711412440.xml 3 1715
2 EX-24 chevallardpoa.htm EX-24 2600
3 chevallardpoa001.jpg GRAPHIC 168196
  Complete submission text file 0001815776-24-000015.txt   237739
Mailing Address C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121
Business Address
Chevallard Daniel R. (Reporting) CIK: 0001706176 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40532 | Film No.: 24780669

Mailing Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014
Business Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014 858-925-7000
LENZ Therapeutics, Inc. (Issuer) CIK: 0001815776 (see all company filings)

IRS No.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)